The effects of vortioxetine on patients with depression and its effects on the brain-derived neurotrophic factor and norepinephrine levels

Objective: The purpose of this study was to investigate the effects of vortioxetine in patients with depression and to evaluate any changes in the brain-derived neurotrophic factor (BDNF) and norepinephrine (NE) levels. Method: A total of 89 patients with depression were recruited for the study and divided into a study group (the SG, n=44, routine medication + vortioxetine) and a control group (the CG, n=45, routine medication) according to the treatment options. The curative effects, the Hamilton Depression Scale (HAMD) scores before treatment and after 2, 4, and 8 weeks of treatment were evaluated. The Sheehan Disability Scale (SDS) was used to assess the social function at baseline, and after 2, 4, and 8 weeks of treatment. The BDNF and NE levels were compared before the treatment and after 8 weeks of treatment. Results: The curative effect in the SG was better than it was in the CG (P<0.05). Compared with the CG, the SG exhibited lower HAMD and SDS scores after 2, 4, and 8 weeks of treatment, and higher BDNF and NE levels after 8 weeks of treatment (P<0.05); There was a statistically significant difference in the incidence of adverse events between the two groups. Conclusion: The efficacy of vortioxetine for depression is supported by lower HAMD scores, a higher social function, improved serum BDNF and NE levels, and higher treatment safety.